塞来昔布抗乳腺癌的临床应用  

Clinical Application of Celecoxib's Anti- Breast Cancer

作　　者：余文韬[1] 蒋刚[1] 

机构地区：[1]四川省肿瘤医院药学部,四川成都610041

出　　处：《中国药业》2013年第23期1-3,共3页China Pharmaceuticals

摘　　要：目前研究发现环氧化酶-2(COX-2)与乳腺癌的发生有密切联系。COX-2及其催化产物前列腺素(PGs)参与炎症的多种过程,且可通过多种致病机制参与多种实体瘤的发生、发展过程。塞来昔布作为新型非甾体类抗炎药(NASIDs),是一种高选择性的COX-2抑制剂,国内外的研究表明,其对上皮组织癌有一定的抑制作用。该文就塞来昔布抗乳腺癌的机制及其临床研究进行了综述。The recent researches show that cyclooxygenase-2（COX-2） has a close connection to the occurrence of breast cancer. COX-2 and its catalysate prostaglandins（PGs） not only participate in the multiple processes of inflammation, but also involve in the occurrence and development processes of multiple solid tumors. Celecoxib as a new type non- steroid anti- inflammatory drug is a highly selective COX- 2 inhibitor. The reports at home and abroad indicate that celecoxib has certain inhibiting effect on epithelial carcinoma. This article reviews the celecoxib＇s anti- breast cancer mechanism and clinical researches.

关 键 词：环氧化酶-2抑制剂 塞来昔布 乳腺癌 

分 类 号：R971.1[医药卫生—药品]